Michael Scott, DO
Internal Medicine · New Albany, MSNPI 1275535551
Payments from drug & device makers
Across 73 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$184
- Amgen$139
- Takeda Pharmaceuticals U.S.A., Inc.$119
- Pfizer$111
- Merck$89
- Supernus Pharmaceuticals, Inc.$78
- plus $531 from 19 others
What the payments were for
- Food & beverage$1,251100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $184 |
| Amgen | 10 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $119 |
| Pfizer | 7 | $111 |
| Merck | 5 | $89 |
| Supernus Pharmaceuticals, Inc. | 4 | $78 |
| Inspire Medical Systems, Inc. | 1 | $63 |
| GE HealthCare | 1 | $63 |
| GSK | 4 | $61 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Boston Scientific | 2 | $48 |
| Shire North American Group Inc | 3 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Lilly USA, LLC | 2 | $24 |
| Tris Pharma Inc | 1 | $19 |
| Corium, LLC | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Heartflow, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| VBI Vaccine (delaware) Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Bristol Myers Squibb | 1 | $11 |
How this compares
$1,251 in reported general payments places this provider in the 65th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $84,626 |
| JardianceEmpagliflozin | 56 | $52,537 |
| TrulicityDulaglutide | 39 | $48,138 |
| EliquisApixaban | 36 | $37,599 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $37,080 |
| FarxigaDapagliflozin Propanediol | 30 | $25,980 |
| MounjaroTirzepatide | 18 | $22,659 |
| JanuviaSitagliptin Phosphate | 19 | $18,559 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $17,376 |
| XareltoRivaroxaban | 24 | $15,927 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 48 | $15,429 |
| MyrbetriqMirabegron | 24 | $14,029 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 37 | $11,785 |
| GlyxambiEmpagliflozin/Linagliptin | 17 | $9,735 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 42 | $9,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $24 | $70,79857 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta | $61 | $64,750124 claims |
| Boehringer IngelheimJardiance, Glyxambi | $13 | $62,27173 claims |
| PfizerEliquis, Abrysvo | $111 | $53,02784 claims |
| AstraZenecaFarxiga | $12 | $25,98030 claims |
| MerckJanuvia | $89 | $18,55919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in New Albany
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.